Coronavirus disease 2019 induces multi-lineage, morphologic changes in peripheral blood cells.

COVID‐19 SARS‐CoV‐2 blood differential count hemato‐morphology peripheral blood smear

Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 07 06 2020
revised: 11 06 2020
accepted: 12 06 2020
pubmed: 25 8 2020
medline: 25 8 2020
entrez: 25 8 2020
Statut: epublish

Résumé

The clinical course of coronavirus disease 2019 (COVID-19) varies from mild symptoms to acute respiratory distress syndrome, hyperinflammation, and coagulation disorder. The hematopoietic system plays a critical role in the observed hyperinflammation, particularly in severely ill patients. We conducted a prospective diagnostic study performing a blood differential analyzing morphologic changes in peripheral blood of COVID-19 patients. COVID-19 associated morphologic changes were defined in a training cohort and subsequently validated in a second cohort (n = 45). Morphologic aberrations were further analyzed by electron microscopy (EM) and flow cytometry of lymphocytes was performed. We included 45 COVID-19 patients in our study (median age 58 years; 82% on intensive care unit). The blood differential showed a specific pattern of pronounced multi-lineage aberrations in lymphocytes (80%) and monocytes (91%) of patients. Overall, 84%, 98%, and 98% exhibited aberrations in granulopoiesis, erythropoiesis, and thrombopoiesis, respectively. Electron microscopy revealed the ultrastructural equivalents of the observed changes and confirmed the multi-lineage aberrations already seen by light microscopy. The morphologic pattern caused by COVID-19 is characteristic and underlines the serious perturbation of the hematopoietic system. We defined a hematologic COVID-19 pattern to facilitate further independent diagnostic analysis and to investigate the impact on the hematologic system during the clinical course of COVID-19 patients.

Identifiants

pubmed: 32838398
doi: 10.1002/jha2.44
pii: JHA244
pmc: PMC7361732
doi:

Types de publication

Journal Article

Langues

eng

Pagination

376-383

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

The authors declare no competing interests and no financial support for this study.

Auteurs

Florian Lüke (F)

Department of Internal Medicine III, Haematology and Oncology University Hospital Regensburg Regensburg Germany.

Evelyn Orsó (E)

Institute for Clinical Chemistry and Laboratory Medicine University Hospital Regensburg Regensburg Germany.

Jana Kirsten (J)

Institute for Clinical Chemistry and Laboratory Medicine University Hospital Regensburg Regensburg Germany.

Hendrik Poeck (H)

Department of Internal Medicine III, Haematology and Oncology University Hospital Regensburg Regensburg Germany.

Matthias Grube (M)

Department of Internal Medicine III, Haematology and Oncology University Hospital Regensburg Regensburg Germany.

Daniel Wolff (D)

Department of Internal Medicine III, Haematology and Oncology University Hospital Regensburg Regensburg Germany.

Ralph Burkhardt (R)

Institute for Clinical Chemistry and Laboratory Medicine University Hospital Regensburg Regensburg Germany.

Dirk Lunz (D)

Department of Anesthesiology University Hospital Regensburg Regensburg Germany.

Matthias Lubnow (M)

Department of Internal Medicine II University Hospital Regensburg Regensburg Germany.

Barbara Schmidt (B)

Institute of Clinical Microbiology and Hygiene University Hospital Regensburg Germany.

Florian Hitzenbichler (F)

Department of Infection Prevention and Infectious Diseases University Hospital Regensburg Regensburg Germany.

Frank Hanses (F)

Department of Infection Prevention and Infectious Diseases University Hospital Regensburg Regensburg Germany.

Bernd Salzberger (B)

Department of Infection Prevention and Infectious Diseases University Hospital Regensburg Regensburg Germany.

Matthias Evert (M)

Institute of Pathology University of Regensburg Regensburg Germany.

Wolfgang Herr (W)

Department of Internal Medicine III, Haematology and Oncology University Hospital Regensburg Regensburg Germany.

Christoph Brochhausen (C)

Institute of Pathology University of Regensburg Regensburg Germany.

Tobias Pukrop (T)

Department of Internal Medicine III, Haematology and Oncology University Hospital Regensburg Regensburg Germany.

Albrecht Reichle (A)

Department of Internal Medicine III, Haematology and Oncology University Hospital Regensburg Regensburg Germany.

Daniel Heudobler (D)

Department of Internal Medicine III, Haematology and Oncology University Hospital Regensburg Regensburg Germany.

Classifications MeSH